BUILDING 3, 418 GUILIN ROAD, SHANGHAI, F4
Acquisition Completed
Announces Shareholders’ Approval of Merger Agreement
Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Extraordinary General Meeting
Material disclosure
Investor Frequently Asked Questions
Voting and Support Agreement
Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
Annual and Transition Report of Foreign Private Issuers
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
No filings found
Notification Filed by a National Security Exchange
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
S-8 POS
Correspondence
Submission Upload